Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Oric Pharmaceuticals (ORIC) Operating Income (2019 - 2026)

Oric Pharmaceuticals filings provide 8 years of Operating Income readings, the most recent being -$39.6 million for Q1 2026.

  • Quarterly Operating Income fell 21.09% to -$39.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$149.9 million through Mar 2026, down 2.24% year-over-year, with the annual reading at -$143.0 million for FY2025, 0.08% changed from the prior year.
  • Operating Income hit -$39.6 million in Q1 2026 for Oric Pharmaceuticals, down from -$34.6 million in the prior quarter.
  • Across five years, Operating Income topped out at -$20.7 million in Q2 2022 and bottomed at -$39.6 million in Q1 2026.
  • Average Operating Income over 5 years is -$31.1 million, with a median of -$31.4 million recorded in 2023.
  • The largest annual shift saw Operating Income tumbled 44.11% in 2024 before it grew 12.68% in 2025.
  • Oric Pharmaceuticals' Operating Income stood at -$22.1 million in 2022, then plummeted by 42.09% to -$31.4 million in 2023, then dropped by 25.91% to -$39.6 million in 2024, then increased by 12.68% to -$34.6 million in 2025, then dropped by 14.67% to -$39.6 million in 2026.
  • Per Business Quant, the three most recent readings for ORIC's Operating Income are -$39.6 million (Q1 2026), -$34.6 million (Q4 2025), and -$36.7 million (Q3 2025).